TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01519115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early physical therapy intervention
Description: instruction in home care program to be followed for first six weeks after ACF surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: one physical therapy visit in hospital following ACF surgery
Study: NCT00376688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT03403972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 250Mg Capsule
Description: Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
Study: NCT02862912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Administered as a single injection or continuously through an indwelling catheter - 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
Study: NCT02413515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat GITS, BAY1040)
Description: Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
Study: NCT04419415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast with high protein dairy
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast with high protein dairy
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will be asked to participate in organized exercise training 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will be asked to participate in organized exercise training 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping breakfast
Description: Participants will be asked to skip breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping breakfast
Description: Participants will be asked to skip breakfast.
Study: NCT02838550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Online Intervention
Description: The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Online Intervention
Description: The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
Study: NCT04905329

Intervention type: DRUG
Intervention: Empegfilgrastim
Description: Extimia®

Intervention type: DRUG
Intervention: Empegfilgrastim
Description: Extimia®

Intervention type: DRUG
Intervention: Empegfilgrastim
Description: Extimia®
Study: NCT02585804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral tablet, 10mg, PO, 8 weeks
Study: NCT03161418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-910638G, 0.4 mg
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-910638G, 1.2 mg
Description: The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
Study: NCT01050062

Intervention type: DRUG
Intervention: Telmisartan 80mg
Description: Combination tablet

Intervention type: DRUG
Intervention: Telmisartan 40mg
Description: Combination tablet

Intervention type: DRUG
Intervention: Hydrochlorothiazide 12.5mg
Description: Combination tablet

Intervention type: DRUG
Intervention: Hydrochlorothiazide 12.5mg
Description: Combination tablet
Study: NCT00325572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral zinc and vitamin C supplements
Description: Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral Placebo
Description: Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
Study: NCT02378753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV
Description: The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV
Description: The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
Study: NCT03196713

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early Intensive Behavioral Intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early Intensive Behavioral Intervention
Study: NCT04323189

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin 100mg
Description: Sitagliptin will be administered daily for 7 days, with a study day on day 7.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin 100mg
Description: Sitagliptin will be administered daily for 7 days, with a study day on day 7.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Placebo will be administered daily for 7 days, with a study day on day 7.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Placebo will be administered daily for 7 days, with a study day on day 7.
Study: NCT01732224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + Telbivudine
Description: Tenofovir (300 mg/day) plus telbivudine (600 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
Study: NCT01214174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Study: NCT03689933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root analog implant
Description: a custom made root analogue implant made from milled titanium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root analog implant
Description: a custom made root analogue implant made from milled titanium
Study: NCT01802970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra plus Standard of Care
Description: Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
Study: NCT00579007

Intervention type: BEHAVIORAL
Intervention: telephone interviews
Description: Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
Study: NCT03551080

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline administered intravenously
Study: NCT02394860

Intervention type: OTHER
Intervention: echo Doppler lower limbs
Study: NCT02626351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline data collection (active comparator)
Description: Endpoint data collection only
Study: NCT01570192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV meropenem
Description: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V. Meropenem
Description: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Study: NCT02625974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT04436198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MORCHER® EYEJET® CTR Types 14, 14A, and 14C
Description: Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric IOL Only
Description: Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care).
Study: NCT02977403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Retraining
Description: Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: AB Control
Description: Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location
Study: NCT01094457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin, clopidogrel
Description: patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel, cilostazol
Description: Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
Study: NCT03592420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary multicomponent interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: standard care
Study: NCT01347749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness & Compassion Meditation-based Exposure Therapy
Description: A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy for PTSD
Description: This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
Study: NCT03447535

Intervention type: OTHER
Intervention: Semi-directive interview (Kiddy Sads)
Description: semi-directive interview (Kiddy Sads) conducted as part of the care

Intervention type: OTHER
Intervention: Semi-directive interview (Kiddy Sads)
Description: semi-directive interview (Kiddy Sads) conducted as part of the care

Intervention type: OTHER
Intervention: SDQ questionnaires (strenghs and difficulties questionnaire)
Description: SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care

Intervention type: OTHER
Intervention: SDQ questionnaires (strenghs and difficulties questionnaire)
Description: SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
Study: NCT02277093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study: NCT04651335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: afferent virtual reality program
Description: When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: efferent virtual reality program
Description: When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
Study: NCT03459339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscopy (TCE)
Description: Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
Study: NCT00595153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmicort
Description: inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmicort
Description: inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
Study: NCT04699084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mozart music
Description: A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
Study: NCT03502811

Intervention type: DEVICE
Intervention: MitraClip NTR/XTR System
Description: Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
Study: NCT03036228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karonudib
Description: Dose escalation of administration with Karonudib.
Study: NCT03783897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
Study: NCT01570192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
Description: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
Description: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
Description: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tobramycin nebulization
Description: tobramycin nebulization 600mg/day
Study: NCT01986751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study: NCT03422471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Hypoglycemic Clamp
Description: Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
Study: NCT01347957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) Gel
Description: Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.